News25/Ratings12
News · 26 weeks48-25%
2025-12-142026-06-07
Mix1890d
- SEC Filings8(44%)
- Insider4(22%)
- Analyst2(11%)
- Earnings2(11%)
- Offering1(6%)
- Other1(6%)
Latest news
25 items- INSIDERChief Medical Officer Drappa Jorn exercised 26,852 shares at a strike of $6.65, increasing direct ownership by 83% to 59,339 units (SEC Form 4)4 - ALUMIS INC. (0001847367) (Issuer)
- SECSEC Form DEFA14A filed by Alumis Inc.DEFA14A - ALUMIS INC. (0001847367) (Filer)
- SECSEC Form DEF 14A filed by Alumis Inc.DEF 14A - ALUMIS INC. (0001847367) (Filer)
- ANALYSTAlumis downgraded by H.C. Wainwright with a new price targetH.C. Wainwright downgraded Alumis from Buy to Neutral and set a new price target of $25.00
- SECSEC Form 10-Q filed by Alumis Inc.10-Q - ALUMIS INC. (0001847367) (Filer)
- SECAlumis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ALUMIS INC. (0001847367) (Filer)
- PRAlumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms – – Data showed robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) – – Data continue to underscore envudeucitinib's potential as a leading oral therapy for PsO; plans to submit NDA in 4Q 2026 remain on track – – Potentially pivotal Phase 2b topline data for envudeucitinib in systemic lupus erythematosus (SLE) anticipated 3Q 2026 – SOUT
- INSIDERSEC Form 4 filed by Foresite Labs, Llc4 - ALUMIS INC. (0001847367) (Issuer)
- INSIDERSEC Form 4 filed by Foresite Capital Management Vi Llc4 - ALUMIS INC. (0001847367) (Issuer)
- INSIDERSEC Form 4 filed by Tananbaum James B.4 - ALUMIS INC. (0001847367) (Issuer)
- SECAlumis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ALUMIS INC. (0001847367) (Filer)
- PRAlumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque PsoriasisEnvudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality‑of‑life improvements and itch relief emerged ahead of PASI 90 skin clearance, and clear or almost clear scalp psoriasis emerged by Week 4, highlighting envudeucitinib's early onset and broad clinical benefitEnvudeucitinib demonstrated a favorable safety and tolerability profile consistent with the Phase 2 programResults presented as a late-breaking oral presentation at the 2026 American Academy of Dermatology (AAD) Annual MeetingConference call and webcast scheduled for March 29, 2026, at 5:00 pm MDT / 7:00 pm EDT SOUTH SAN
- SECSEC Form S-3ASR filed by Alumis Inc.S-3ASR - ALUMIS INC. (0001847367) (Filer)
- SECSEC Form 10-K filed by Alumis Inc.10-K - ALUMIS INC. (0001847367) (Filer)
- SECAlumis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ALUMIS INC. (0001847367) (Filer)
- PRAlumis Reports Year End 2025 Financial Results and Highlights Recent Achievements– Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis (PsO) – – Plan to submit NDA for envudeucitinib in PsO in 2H 2026 – – Potentially pivotal Phase 2b clinical topline data for envudeucitinib in systemic lupus erythematosus (SLE) anticipated 3Q 2026 – – Presentation of additional Phase 3 ONWARD1 and ONWARD2 data at AAD 2026 – – Completed an upsized public offering raising $345.1 million in gross proceeds in Jan 2026 – SOUTH SAN FRANCISCO, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma com
- PRAlumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting– Phase 3 data presentation highlighting results from the ONWARD1 and ONWARD2 clinical trials of envudeucitinib – – Phase 2 STRIDE e-poster presentation to describe disease biomarker activity of envudeucitinib – – Alumis to host investor webcast on Sunday, March 29, 2026, at 5:00 pm MDT / 7:00 pm EDT – SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that results from its Phase 3 ONWARD program evaluating envudeucitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe pl
- ANALYSTRaymond James initiated coverage on Alumis with a new price targetRaymond James initiated coverage of Alumis with a rating of Strong Buy and set a new price target of $46.00
- PRAlumis to Present at the Leerink Partners Global Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026, at 10:40 a.m. ET. A live webcast will be available on the Alumis website in the "Investors" section under the "Events" page. A replay of the conference webcast will be archived on the company's website for 90 days. About Alumis Alumis is a late-stage biopharma company developing next
- ANALYSTStifel initiated coverage on Alumis with a new price targetStifel initiated coverage of Alumis with a rating of Buy and set a new price target of $44.00
- INSIDERGoldstein David M transferred by will 1,000 shares) (SEC Form 5)5 - ALUMIS INC. (0001847367) (Issuer)
- PRAlumis to Participate in Upcoming February Investor ConferencesSOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026February 11-12, 2026, New York, NYFireside chat: Thursday, February 12, 2026 at 9:00 am ET Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 25-26, 2026, VirtualPresentation: Thursday, February 26, 2026 at 3:20 pm ET To access the live webcasts please visit the "Events" page of the "Investors" section of the Alumis website. Web
- SECSEC Form S-8 filed by Alumis Inc.S-8 - ALUMIS INC. (0001847367) (Filer)
- INSIDERSEC Form 4 filed by Chief Legal Officer Pangali Sanam4 - ALUMIS INC. (0001847367) (Issuer)
- INSIDERSEC Form 4 filed by President, CEO and Chairman Babler Martin4 - ALUMIS INC. (0001847367) (Issuer)
ALMS FAQ
6 questionsWhere does ALMS stock trade?
Alumis Inc. (ALMS) is listed on NASDAQ.What sector and industry is ALMS in?
Alumis Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Alumis Inc. go public?
Alumis Inc. (ALMS) completed its IPO in 2024.What are analysts saying about ALMS?
Alumis Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral with a $2500.00 price target on 2026-05-15. Recent price targets range from $1700.00 to $4600.00.What companies are similar to ALMS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ALMS side-by-side with any of them on Quantisnow.How can I track ALMS on Quantisnow?
Quantisnow aggregates Alumis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALMS to receive live email and push alerts on every new disclosure.